Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis exec moves to J&J

Executive Summary

Head of Novartis' North American pharmaceuticals unit Alex Gorsky resigns, the firm announces Feb. 14. Gorsky will join Johnson & Johnson as group chairman of the firm's medical device company Ethicon. Before joining Novartis in 2004 as Chief Operating Officer and Head of General Medicines, Gorsky served as company group chairman for J&J's pharmaceutical business in Europe, the Middle East and Africa. Gorsky will report to J&J Worldwide Chairman for Surgical Care Sheri McCoy...

You may also be interested in...



Novartis North America pharma head

Ludwig Hantson becomes head of Novartis' North America pharma business, the company announces April 10. Hantson, who led Novartis' Specialty Medicines Operating Unit, replaces Alex Gorsky effective immediately (1"The Pink Sheet," Feb. 25, 2008, In Brief). Among other challenges, Hantson will have to determine the best course of action for Novartis' DPP-4 inhibitor Galvus (vildagliptin) following an approvable letter in 2007

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

UsernamePublicRestriction

Register

PS049342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel